Učitavanje...
Measurement of mucosal biomarkers in a phase 1 trial of intravaginal 3% SPL 7013 gel (VivaGel(®)) to assess expanded safety
OBJECTIVE: The aim of this study was to examine the effect of the 3% SPL 7013 gel (VivaGel(®)) on mucosal immune markers hypothesized to be associated with HIV-1 acquisition. DESIGN: Phase 1, placebo-controlled, randomized, double-blind clinical trial was performed in 54 young women in the U.S. and...
Spremljeno u:
| Glavni autori: | , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
2012
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3261360/ https://ncbi.nlm.nih.gov/pubmed/22067666 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/QAI.0b013e31823f2aeb |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|